FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
about
Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisCo-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Predicting Chemotherapy Resistance in AML.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Method development for quantification of quizartinib in rat plasma by liquid chromatography/tandem mass spectrometry for pharmacokinetic application.Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach.Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.
P2860
Q33749036-6F698CE7-099B-4F90-86A2-9BA0BBC86C83Q33838356-8EDBCE24-1C60-42D0-BA41-25DB076E34F2Q37565024-ADBB045B-2357-4100-AF58-E09C1B2D40C7Q38675400-83C73154-0AFD-4BF4-90C8-E3ABA33254B0Q38913785-12FE5DDE-7C2C-4305-A0A6-367C373E6377Q39175665-81EECD2F-0546-4A1A-8D40-EEEECAAD307DQ39233284-252C4EC4-32FC-491D-BF79-329DFB42F87AQ40401088-E18A0FC9-208D-4B7D-9341-0EC89DAFF8A3Q41843892-125024DE-A2C4-461F-B863-6B5D3D99FA1DQ42363757-1756A8A3-2A2B-4981-800D-F3CFBD802566Q46544283-33DCD335-7F56-4FAA-8F03-2B609D3F3C23Q47104275-ED7921E4-EECF-4E66-B758-70F5B5CB82ACQ47150923-14AEAF4F-C9B7-497F-B33D-D8C163A9531DQ47439297-1A939090-88CE-4858-B8D4-99E7C97CF965Q47818563-FF2D53C1-38D0-42FB-8C70-AA49D504E0C9Q49311338-CEC9DF76-BDDB-45EE-858E-CF0ECC9BFDCEQ50066002-26AAF385-EC2E-4B5A-9749-008A5C98969DQ53110467-CE6C8729-C66D-443A-A2A4-B7098D8F3791Q54160284-9B5C55A0-FDC1-4013-92F6-D9A5BE8C0EEBQ54956859-0BEB3CF4-9FC8-4D15-8AA8-D1FA2581FD36
P2860
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@ast
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@en
type
label
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@ast
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@en
prefLabel
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@ast
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@en
P2093
P2860
P356
P1433
P1476
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2015.165
P577
2015-06-25T00:00:00Z